Quarterly report [Sections 13 or 15(d)]

Schedule of Reconciliation Consolidated Net Loss (Details)

v3.26.3
Schedule of Reconciliation Consolidated Net Loss (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]        
Total Sales
Total Cost of Sales
Gross Profit
Total Administrative Expenses 1,097,572 967,833 3,630,013 2,703,815
Total Research and Development Expenses 383,382 356,352 1,130,049 2,775,337
Total Stock Based Compensation 860,667 5,343,060 189,490
Total Franchise Tax Expense 123,654 200,050 343,057 200,050
Total Warrant Issuance Expenses 264,417 264,417
Total Transaction costs associated with due diligence 100,000 100,000
Total Segment Net Loss 2,565,275 1,788,652 10,546,179 6,133,109
Adjustments and Reconciling Items        
Total Interest and Dividend Income 55,477 35,955 227,442 156,042
Total Gain (Loss) on Sales of Marketable Securities 24,410 55,651 2,176
Total Unrealized Gain (Loss) on Marketable Securities 2,595 309 (4,695) (1,435)
Total Change in Fair Value of Derivative Liabilities 1,541,000 (1,059,000) 2,132,000 244,000
Total Impairment of Technology License (3,177,999)
Total Adjustments and Reconciling Items 1,623,482 (1,022,736) (767,601) 400,783
Consolidated Net Loss (941,793) (2,811,388) (11,313,780) (5,732,326)
Pharmaceuticals Segment [Member]        
Segment Reporting [Line Items]        
Total Sales
Total Cost of Sales
Total Administrative Expenses 109,757 967,833 363,001 2,703,815
Total Research and Development Expenses 4,074 356,352 28,172 2,775,337
Total Stock Based Compensation 189,490
Total Franchise Tax Expense 12,365 200,050 34,306 200,050
Total Warrant Issuance Expenses 264,417 264,417
Total Transaction costs associated with due diligence
Total Segment Net Loss 126,196 1,788,652 425,479 6,133,109
Adjustments and Reconciling Items        
Total Interest and Dividend Income 35,955 156,042
Total Gain (Loss) on Sales of Marketable Securities 2,176
Total Unrealized Gain (Loss) on Marketable Securities 309 (1,435)
Total Change in Fair Value of Derivative Liabilities (1,059,000) 244,000
Total Impairment of Technology License
Total Adjustments and Reconciling Items (1,022,736) 400,783
Consolidated Net Loss (126,196) (2,811,388) (425,479) (5,732,326)
Computing Technology Segment [Member]        
Segment Reporting [Line Items]        
Total Sales
Total Cost of Sales
Total Administrative Expenses 987,815 3,267,012
Total Research and Development Expenses 379,308 1,101,877
Total Stock Based Compensation 860,667 5,343,060
Total Franchise Tax Expense 111,289 308,751
Total Warrant Issuance Expenses
Total Transaction costs associated with due diligence 100,000 100,000
Total Segment Net Loss 2,439,079 10,120,700
Adjustments and Reconciling Items        
Total Interest and Dividend Income 55,477 227,442
Total Gain (Loss) on Sales of Marketable Securities 24,410 55,651
Total Unrealized Gain (Loss) on Marketable Securities 2,595 (4,695)
Total Change in Fair Value of Derivative Liabilities 1,541,000 2,132,000
Total Impairment of Technology License (3,177,999)
Total Adjustments and Reconciling Items 1,623,482 (767,601)
Consolidated Net Loss $ (815,597) $ (10,888,301)